BioSpace News Archive

Aclaris Therapeutics, Inc. announced that it has appointed Robert A. Doody Jr. as Vice President, Investor Relations.

Voyager Therapeutics, Inc., a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus capsids, announced that management will participate in the following investor conferences.

Clearside Biomedical, Inc. announced that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present a corporate overview at the Eyecelerator conference on September 29, 2022, as part of the Annual Meeting of the American Academy of Ophthalmology, the world’s largest association of eye physicians and surgeons.

Bausch + Lomb Corporation announced the presentation of one podium and two poster presentations at the World Cornea Congress VIII meeting, which will take place in Chicago from Sept. 28-29, 2022.

Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® blood glucose monitoring system portfolio and exclusive distributor of Eversense® Continuous Glucose Monitoring Systems, announces that it has relaunched its successful ‘This is Diabetes’ art and photo competition in support of World Diabetes Day 2022.

BioLineRx Ltd. announced its U.S. commercialization plan for APHEXDA in stem cell mobilization for autologous bone marrow transplantation for multiple myeloma patients.

Silence Therapeutics plc announced that Giles Campion, MD, Head of R&D and Chief Medical Officer, will participate in a fireside chat at the Chardan Genetic Medicines Conference on Tuesday, October 4th at 3:45 p.m. ET in New York.

DEM BioPharma, Inc. established its C-suite and scientific leadership teams with the appointment of Nenad Grmusa as Chief Executive Officer and Christophe Quéva, Ph.D., as Chief Scientific Officer.

Aura Biosciences, Inc. today announced that data from the ongoing Phase 2 trial evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC product candidate, belzupacap sarotalocan (AU-011).

AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors has elected Lorence H. Kim, M.D., 48, as a new independent director, effective October 1, 2022.